Several previous cross‐sectional studies have researched the role of muscle quantity in the prediction of PFS or OS with regard to PD‐1/PD‐L1 inhibitor use in patients with advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.